Reverse Total Shoulder Arthroplasty Clinical Trial
Official title:
Reverse Total Shoulder Arthroplasty in Patients Who Exceeded Their Life-expectancy: a Retrospective Study
Verified date | March 2021 |
Source | Bürgerspital Solothurn |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Reverse total shoulder arthroplasty (RTSA) has become an established treatment for cuff arthropathy, severe osteoarthritis and in certain fracture cases. Due to the increasingly aging population, patients who have already exceeded their life-expectancy pose a significant challenge to the shoulder surgeon. Therefore, we wanted to investigate patient demographics, hospital stay length, complication rate functional outcome, patient reported outcome scores and mortality retrospectively for patients, who were older than 83 years at time of implantation of a RTSA.
Status | Completed |
Enrollment | 110 |
Est. completion date | December 21, 2020 |
Est. primary completion date | August 4, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 83 Years and older |
Eligibility | Inclusion Criteria: - Patients older than 83 years at time of surgery - Patients who received a reverse total shoulder arthroplasty Exclusion Criteria: - Patients younger than 83 years at time of surgery |
Country | Name | City | State |
---|---|---|---|
Switzerland | Bürgerspital Solothurn | Solothurn |
Lead Sponsor | Collaborator |
---|---|
Bürgerspital Solothurn |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient reported outcome score: ASES | American Shoulder and Elbow Society (ASES) Score | until august 2020 | |
Primary | Complication rate | postoperative complications requiring surgical intervention | until august 2020 | |
Primary | Quality adjusted life year (QALY) | The quality adjusted life year (QALY) ) is a well-established indicator of the life quality for the remaining years and was calculated as the years of life following the operation, multiplied by the utility value, for the current study, defined as the postoperative American Shoulder and Elbow Surgeons Shoulder Score (ASES) score (0-1 points) at last follow-up. | until august 2020 | |
Primary | Mortality | Survivership | until august 2020 | |
Primary | Patient reported outcome score: QuickDASH | Quick Disabilities of the arm, shoulder and hand (DASH) Score, | until august 2020 | |
Primary | Patient reported outcome score: VAS | Visual analog score (VAS) | until august 2020 | |
Secondary | Patient demographics | male/female ratio, age, BMI, ASA (American Society of Anesthesiologists) classification, hospital stay length, range of motion | at time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05900427 -
Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients
|
Phase 4 | |
Completed |
NCT02569658 -
Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty
|
N/A | |
Enrolling by invitation |
NCT05789784 -
Study of Zimmer Biomet Mymobility Application on Reverse Total Shoulder Arthroplasty (RTSA) Outcomes
|
N/A | |
Not yet recruiting |
NCT06292169 -
Pectoralis Minor Release Versus Non-release in RSA
|
N/A | |
Completed |
NCT02052466 -
Prediction of Development of Scapular Notching Following Reverse Total Shoulder Arthroplasty
|
N/A | |
Recruiting |
NCT06133920 -
Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures
|
||
Enrolling by invitation |
NCT02014350 -
Outcomes Following Delta Xtend Reverse Shoulder System
|
N/A |